PEGASUS: A Phase III Study to Evaluate the Efficacy and Safety of APL-2 in Patients With PNH | Aplastic Anemia & MDS International Foundation

ClinicalTrials.gov Identifier:

NCT03500549

Company

Apellis Pharmaceuticals

Contact Info

Allen Papazian
(617) 977-5700
clinicaltrials@apellis.com

Dates

Start: June 2018

Official Title

PEGASUS: A Phase III Study to Evaluate the Efficacy and Safety of APL-2 in Patients With PNH

Purpose

The purpose of this study is to establish the efficacy and safety of APL-2 compared to eculizumab in patients with PNH who continue to have Hb levels <10.5 g/dL despite treatment with eculizumab (Soliris®). This study will enroll approximately 70 subjects around the globe to compare APL-2 to eculizumab treatment. All subjects who qualify will receive APL-2.

For more information visit the Pegasus Study Website »

PEGASUS: A Phase III Study to Evaluate the Efficacy and Safety of APL-2 in Patients With PNH

Clinical Trial: NCT03500549

Instructions

If you are interested in learning more about your possible participation in this clinical trial, please complete the form. Your information will be forwarded directly to the sponsoring company.

Status: 
Recruiting
Associated Drug(s): 
Phase: 
Phase 3
Gender: 
Female
Male
Age Group: 
18 years and older
Accepts Healthy Volunteers: 
No
Inclusion Criteria: 
  • At least 18 years of age, with primary diagnosis of PNH confirmed by high-sensitivity flow cytometry
  • On treatment with stable dose of eculizumab for at least 3 months.
  • Hb <10.5 g/dL
  • Absolute reticulocyte count >1.0x ULN
  • Platelet count of >50,000/mm3
  • Absolute neutrophil count >500/mm3
  • BMI <= 40 kg/m2
  • Have or are willing to receive vaccination against Neisseria meningitides (types A, C, W, Y and B), Streptococcus pneumoniae and Haemophilus influenzae Type B (Hib)
  • Women of child-bearing potential (WOCBP) must have a negative pregnancy test and must agree to use protocol defined methods of contraception for the duration of the study and 90 days after their last dose of study drug
  • Males must agree to use protocol defined methods of contraception and agree to refrain from donating sperm for the duration of the study and 90 days after their last dose of study drug
  • Willing and able to give informed consent
  • Willing and able to self-administer APL-2 (administration by caregiver will be allowed)
Exclusion Criteria: 
  • Active bacterial infection that has not resolved within 1 week before starting study drug
  • Receiving unstable doses of iron, folic acid, vitamin B12 or EPO within 4 weeks before study start
  • Hereditary complement deficiency
  • History of bone marrow transplantation
  • Participation in any other investigational drug trial or exposure to other investigational agent within 30 days or 5 half-lives (whichever is longer)
  • Currently breast-feeding women
  • History or family history of Long QT Syndrome or torsade de pointes, unexplained syncope, syncope from an uncorrected cardiac etiology, or family history of sudden death
  • Myocardial infarction, CABG, coronary or cerebral artery stenting and /or angioplasty, stroke, cardiac surgery, or hospitalization for congestive heart failure within 3 months or greater than Class 2 Angina Pectoris or NYHA Heart Failure Class >2
  • QTcF > 470 ms or PR > 280 ms
  • Mobitz II 2nd degree AV Block, 2:1 AV Block, High Grade AV Block, or Complete Heart Block unless the patient has an implanted pacemaker or implantable cardiac defibrillator (ICD) with backup pacing capabilities
  • Receiving Class 1 or Class 3 antiarrhythmic agents, or arsenic, methadone, ondansetron or pentamidine

Find Out More:

Disclaimer:

AAMDSIF does not recommend, endorse, or make any representation about the efficacy, appropriateness or suitability of any clinical trial listed on this website. Pharmaceutical company sponsored content is highlighted only to give additional information about the trial. All trials are listed on https://clinicaltrials.gov/. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a clinical trial, and never disregard professional medical advice or delay in seeking it because of something you have read on this website.